Home › Companies › Ovid Therapeutics Inc. › 2025-2026

Ovid Therapeutics Inc. 2025-2026 Proxy Voting Records

Compiled from SEC Form N-PX filings and Ovid Therapeutics Inc.’s Form 8-K, filed 2025-07-10 (Item 5.07 on EDGAR). Page generated 02 October 2026.

11Reported items
117Asset managers
569Fund votes
2025-07-09Main meeting date

Proxy season: 2025-2026

Explore Ovid Therapeutics Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Ovid Therapeutics Inc.

These tallies are Ovid Therapeutics Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2025-07-10 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX. Ovid Therapeutics Inc. reported 2 meetings in this season; each is tabulated separately below, with its own filing.

Ovid Therapeutics Inc. — official shareholder meeting results, meeting held 2025-07-09 (Form 8-K, filed 2025-07-10)
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: Kevin Fitzgerald	35,967,512	--	--	11,599,305	8,425,770	Majority: yes
Elect Director: Bart Friedman	39,928,124	--	--	7,638,693	8,425,770	Majority: yes
Proposal 2: The Company's stockholders approved, on an advisory basis, the compensation paid to the Company's named executive officers, as disclosed in the Proxy Statement, by the votes set forth in the table below:	35,433,853	904,185	11,228,779	--	8,425,770	Majority: yes
Proposal 3: The Company's stockholders ratified the selection of KPMG LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2025 by the votes set forth in the table below:	50,820,500	160,264	5,011,823	--	--	Majority: yes
Proposal 4: The Company's stockholders approved a series of alternate amendments to the Company's Amended and Restated Certificate of Incorporation, as amended, to effect, at the option of the Company's board of directors (the " Board "), a reverse stock split	44,239,086	1,914,880	9,838,621	--	--	Majority: yes

Source: Ovid Therapeutics Inc., Form 8-K, filed with the SEC on 2025-07-10 — read the filing on EDGAR.

Ovid Therapeutics Inc. — official shareholder meeting results, meeting held 2026-06-10 (Form 8-K, filed 2026-06-11)
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: Jeremy M. Levin, DPhil, MB BChir	87,219,707	--	--	8,528,008	35,211,213	Majority: yes
Proposal 2: The Company's stockholders approved, on an advisory basis, the compensation paid to the Company's named executive officers, as disclosed in the Proxy Statement, by the votes set forth in the table below:	84,511,953	8,901,691	2,334,071	--	35,211,213	Majority: yes
Proposal 3: The Company's stockholders ratified the selection of KPMG LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2026 by the votes set forth in the table below:	130,845,667	32,505	80,756	--	--	Majority: yes

This meeting is also recorded here as 2026-06-11; both records come from the same filing, so the date should be checked against it.

Source: Ovid Therapeutics Inc., Form 8-K, filed with the SEC on 2026-06-11 — read the filing on EDGAR.

How asset managers voted at the Ovid Therapeutics Inc. 2025-2026 meetings

Each item below shows how the 117 asset managers that disclosed a Ovid Therapeutics Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Ovid Therapeutics Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. ADVISORY APPROVAL OF THE COMPENSATION PAID TO OUR NAMED EXECUTIVE OFFICERS.

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Meeting held 2025-07-09.

Combines 3 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%

FOR: 35,433,853AGAINST: 904,185

Ovid Therapeutics Inc.’s own tally for this item (“Proposal 2: The Company's stockholders approved, on an advisory basis, the compensation paid to the Company's named executive officers, as disclosed in the Proxy Statement, by the votes set forth in the table below:”): 35,433,853 for, 904,185 against, per its Form 8-K filed 2025-07-10 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 71,109,514 outstanding shares: 49.8% for, 1% against (51.1% of the company cast a for/against vote).

The 77 asset managers below cast 98% of the shares they voted on this item FOR (30,437,609 for, 508,253 against).

FOR 77%ABSTAIN 22%

FOR: 30,437,609 (76.5%)AGAINST: 508,253 (1.3%)ABSTAIN: 8,837,479 (22.2%)

Largest asset managers voting on “ADVISORY APPROVAL OF THE COMPENSATION PAID TO OUR NAMED EXECUTIVE OFFICERS.” at Ovid Therapeutics Inc., 2025-2026
Asset manager	For	Against	Abstain	Vote
Affinity Asset Advisors, LLC	8,446,922	0	0	For
Rubric Capital Management LP	0	0	4,983,661	Abstain
BVF INC/IL	0	0	3,853,818	Abstain
BlackRock	3,685,976	0	0	For
Vanguard	3,127,955	0	0	For
Madison Avenue Partners, LP	2,461,921	0	0	For
ACADIAN ASSET MANAGEMENT LLC	1,688,183	0	0	For
KENNEDY CAPITAL MANAGEMENT LLC	1,051,181	457,519	0	For
DRIEHAUS CAPITAL MANAGEMENT LLC	1,400,191	0	0	For
GEODE CAPITAL MANAGEMENT, LLC	1,325,297	0	0	For
Fidelity	1,230,655	0	0	For
State Street	1,165,816	3,868	0	For
ADAGE CAPITAL PARTNERS GP, L.L.C.	1,150,000	0	0	For
WELLS FARGO CLEARING SERVICES, LLC	676,476	0	0	For
Invesco	582,594	0	0	For
Northern Trust	397,822	2,658	0	For
Charles Schwab	270,974	0	0	For
MELLON INVESTMENTS Corp	187,175	0	0	For
STIFEL NICOLAUS & CO INC \MO\	180,000	0	0	For
Velan Capital Investment Management LP	140,000	0	0	For
Equitable	131,971	0	0	For
Renaissance	126,241	0	0	For
QUANTITATIVE MASTER SERIES LLC	108,595	0	0	For
T. Rowe Price	101,712	0	0	For
Nuveen	89,177	0	0	For

Showing the 25 largest of 77 asset managers. See all 77 in the interactive database.

2. ADVISORY APPROVAL OF THE COMPENSATION PAID TO OUR NAMED EXECUTIVE OFFICERS.

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Meeting held 2026-06-10.

Combines 3 wordings of this item as funds reported it.

90% Majority: yes · of votes cast

FOR 90%10%

FOR: 84,511,953AGAINST: 8,901,691

Ovid Therapeutics Inc.’s own tally for this item (“Proposal 2: The Company's stockholders approved, on an advisory basis, the compensation paid to the Company's named executive officers, as disclosed in the Proxy Statement, by the votes set forth in the table below:”): 84,511,953 for, 8,901,691 against, per its Form 8-K filed 2026-06-11 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Share-of-outstanding not shown: votes cast exceed the reported share count, which usually means multiple share classes with different voting rights.

The 67 asset managers below cast 90% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the company's reported shares outstanding.

FOR 90%10%

FOR: 89.7%AGAINST: 10.2%ABSTAIN: 0.0%

Largest asset managers voting on “ADVISORY APPROVAL OF THE COMPENSATION PAID TO OUR NAMED EXECUTIVE OFFICERS.” at Ovid Therapeutics Inc., 2025-2026
Asset manager	For	Against	Abstain	Vote
Janus Henderson	36,039,960	0	0	For
RA CAPITAL MANAGEMENT, L.P.	15,786,493	0	0	For
Federated Hermes	10,708,528	0	0	For
Vanguard	5,836,237	340	6	For
Saturn V Capital Management LP	4,166,666	0	0	For
ADAR1 Capital Management, LLC	0	3,549,089	0	Against
ADAGE CAPITAL PARTNERS GP, L.L.C.	2,695,000	0	0	For
MUTUAL FUND SERIES TRUST	1,934,257	0	0	For
BRAIDWELL LP	1,555,731	0	0	For
Point72	0	1,251,710	0	Against
Ally Bridge Group (NY) LLC	1,244,405	0	0	For
GEODE CAPITAL MANAGEMENT, LLC	0	1,238,420	0	Against
Ensign Peak Advisors, Inc	1,159,108	0	0	For
BALYASNY ASSET MANAGEMENT L.P.	1,143,967	0	0	For
Fidelity	0	1,001,575	0	Against
BlackRock	922,649	4,268	0	For
SILVERARC CAPITAL MANAGEMENT, LLC	0	881,286	0	Against
WELLS FARGO CLEARING SERVICES, LLC	666,638	0	0	For
Two Sigma	0	411,462	0	Against
MARSHALL WACE, LLP	340,051	0	0	For
Invesco	254,593	0	0	For
Renaissance	0	252,777	0	Against
CIBC Capital Markets (Europe) S.A.	0	239,351	0	Against
CIBC WORLD MARKET INC.	0	239,351	0	Against
Northern Trust	0	232,685	0	Against

Showing the 25 largest of 67 asset managers. See all 67 in the interactive database.

3. Election of Class II Directors: Bart Friedman

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2025-07-09.

Combines 2 wordings of this item as funds reported it.

84% Majority: yes · of votes cast

FOR 84%WITHHELD 16%

FOR: 39,928,124WITHHELD: 7,638,693

Ovid Therapeutics Inc.’s own tally for this item (“Elect Director: Bart Friedman”): 39,928,124 for, 7,638,693 withheld, per its Form 8-K filed 2025-07-10 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 71,109,514 outstanding shares: 56% for, 11% withheld (67% of the company cast a for/withheld vote).

The 27 asset managers below cast 100% of the shares they voted on this item FOR (6,960,456 for, 0 against).

FOR 96%

FOR: 6,960,456 (96.2%)ABSTAIN: 275,831 (3.8%)

Largest asset managers voting on “Election of Class II Directors: Bart Friedman” at Ovid Therapeutics Inc., 2025-2026
Asset manager	For	Abstain	Vote
Vanguard	2,960,685	0	For
BlackRock	2,250,033	0	For
Fidelity	1,165,570	0	For
Charles Schwab	135,487	0	For
Equitable	107,491	24,480	For
QUANTITATIVE MASTER SERIES LLC	108,595	0	For
EA Series Trust	0	91,234	Abstain
TIAA	89,177	0	For
Northern Trust	0	49,278	Abstain
Lincoln Financial	44,200	0	For
Exchange Place Advisors Trust	0	39,014	Abstain
AIG/SunAmerica	0	38,133	Abstain
Global X	33,744	0	For
State Street	20,706	0	For
Pacific Life	17,509	0	For
ProShares	0	12,017	Abstain
Bridge Builder Trust	11,488	0	For
DWS	0	9,195	Abstain
Nationwide	8,507	0	For
Principal	0	6,540	Abstain
Calvert	0	4,924	Abstain
T. Rowe Price	3,876	0	For
PENN SERIES FUNDS INC	2,300	0	For
Brinker Capital Destinations Trust	1,088	0	For
Guggenheim	0	541	Abstain

Showing the 25 largest of 27 asset managers. See all 27 in the interactive database.

4. Election of Class II Directors: Kevin Fitzgerald

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2025-07-09.

Combines 2 wordings of this item as funds reported it.

76% Majority: yes · of votes cast

FOR 76%WITHHELD 24%

FOR: 35,967,512WITHHELD: 11,599,305

Ovid Therapeutics Inc.’s own tally for this item (“Elect Director: Kevin Fitzgerald”): 35,967,512 for, 11,599,305 withheld, per its Form 8-K filed 2025-07-10 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 71,109,514 outstanding shares: 50.6% for, 16% withheld (67% of the company cast a for/withheld vote).

The 27 asset managers below cast 100% of the shares they voted on this item FOR (7,009,950 for, 0 against).

FOR 97%

FOR: 7,009,950 (96.9%)ABSTAIN: 226,337 (3.1%)

Largest asset managers voting on “Election of Class II Directors: Kevin Fitzgerald” at Ovid Therapeutics Inc., 2025-2026
Asset manager	For	Abstain	Vote
Vanguard	2,960,685	0	For
BlackRock	2,250,033	0	For
Fidelity	1,165,570	0	For
Charles Schwab	135,487	0	For
Equitable	107,491	24,480	For
QUANTITATIVE MASTER SERIES LLC	108,595	0	For
EA Series Trust	0	91,234	Abstain
TIAA	89,177	0	For
Northern Trust	49,278	0	For
Lincoln Financial	44,200	0	For
Exchange Place Advisors Trust	0	39,014	Abstain
AIG/SunAmerica	0	38,133	Abstain
Global X	33,744	0	For
State Street	20,706	0	For
Pacific Life	17,509	0	For
ProShares	0	12,017	Abstain
Bridge Builder Trust	11,488	0	For
DWS	0	9,195	Abstain
Nationwide	8,507	0	For
Principal	0	6,540	Abstain
Calvert	0	4,924	Abstain
T. Rowe Price	3,876	0	For
PENN SERIES FUNDS INC	2,300	0	For
Brinker Capital Destinations Trust	1,088	0	For
Guggenheim	0	541	Abstain

Showing the 25 largest of 27 asset managers. See all 27 in the interactive database.

5. RATIFICATION OF THE SELECTION OF KPMG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2025.

AUDIT-RELATEDMajority of the votes cast: yes

Meeting held 2025-07-09.

99.6% Majority: yes · of votes cast

FOR 99.6%

FOR: 50,820,500AGAINST: 160,264

Ovid Therapeutics Inc.’s own tally for this item (“Proposal 3: The Company's stockholders ratified the selection of KPMG LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2025 by the votes set forth in the tab”): 50,820,500 for, 160,264 against, per its Form 8-K filed 2025-07-10 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 71,109,514 outstanding shares: 71% for, 0.3% against (72% of the company cast a for/against vote).

The 27 asset managers below cast 99% of the shares they voted on this item FOR (7,145,053 for, 91,234 against).

FOR 99%

FOR: 7,145,053 (98.7%)AGAINST: 91,234 (1.3%)

Largest asset managers voting on “RATIFICATION OF THE SELECTION OF KPMG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL ” at Ovid Therapeutics Inc., 2025-2026
Asset manager	For	Against	Vote
Vanguard	2,960,685	0	For
BlackRock	2,250,033	0	For
Fidelity	1,165,570	0	For
Charles Schwab	135,487	0	For
Equitable	131,971	0	For
QUANTITATIVE MASTER SERIES LLC	108,595	0	For
EA Series Trust	0	91,234	Against
TIAA	89,177	0	For
Northern Trust	49,278	0	For
Lincoln Financial	44,200	0	For
Exchange Place Advisors Trust	39,014	0	For
AIG/SunAmerica	38,133	0	For
Global X	33,744	0	For
State Street	20,706	0	For
Pacific Life	17,509	0	For
ProShares	12,017	0	For
Bridge Builder Trust	11,488	0	For
DWS	9,195	0	For
Nationwide	8,507	0	For
Principal	6,540	0	For
Calvert	4,924	0	For
T. Rowe Price	3,876	0	For
PENN SERIES FUNDS INC	2,300	0	For
Brinker Capital Destinations Trust	1,088	0	For
Guggenheim	541	0	For

Showing the 25 largest of 27 asset managers. See all 27 in the interactive database.

6. TO APPROVE A SERIES OF ALTERNATE AMENDMENTS TO OUR AMENDED AND RESTATED CERTIFICATE OF INCORPORATION TO EFFECT, AT THE OPTION OF OUR BOARD OF DIRECTORS, A REVERSE STOCK SPLIT OF OUR COMMON STOCK AT A RATIO IN THE RANGE OF 1-FOR-10 TO 1-FOR-40, INCLUSIVE, WITH SUCH RATIO TO BE DETERMINED BY OUR BOARD OF DIRECTORS IN ITS SOLE DISCRETION.

CAPITAL STRUCTUREMajority of the votes cast: yes

Meeting held 2025-07-09.

96% Majority: yes · of votes cast

FOR 96%

FOR: 44,239,086AGAINST: 1,914,880

Ovid Therapeutics Inc.’s own tally for this item (“Proposal 4: The Company's stockholders approved a series of alternate amendments to the Company's Amended and Restated Certificate of Incorporation, as amended, to effect, at the option of the Company's board of director”): 44,239,086 for, 1,914,880 against, per its Form 8-K filed 2025-07-10 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 71,109,514 outstanding shares: 62% for, 3% against (65% of the company cast a for/against vote).

The 27 asset managers below cast 100% of the shares they voted on this item FOR (7,236,287 for, 0 against).

FOR 100%

FOR: 7,236,287 (100.0%)

Largest asset managers voting on “TO APPROVE A SERIES OF ALTERNATE AMENDMENTS TO OUR AMENDED AND RESTATED CERTIFICATE OF INCORPORATION TO EFFECT” at Ovid Therapeutics Inc., 2025-2026
Asset manager	For	Vote
Vanguard	2,960,685	For
BlackRock	2,250,033	For
Fidelity	1,165,570	For
Charles Schwab	135,487	For
Equitable	131,971	For
QUANTITATIVE MASTER SERIES LLC	108,595	For
EA Series Trust	91,234	For
TIAA	89,177	For
Northern Trust	49,278	For
Lincoln Financial	44,200	For
Exchange Place Advisors Trust	39,014	For
AIG/SunAmerica	38,133	For
Global X	33,744	For
State Street	20,706	For
Pacific Life	17,509	For
ProShares	12,017	For
Bridge Builder Trust	11,488	For
DWS	9,195	For
Nationwide	8,507	For
Principal	6,540	For
Calvert	4,924	For
T. Rowe Price	3,876	For
PENN SERIES FUNDS INC	2,300	For
Brinker Capital Destinations Trust	1,088	For
Guggenheim	541	For

Showing the 25 largest of 27 asset managers. See all 27 in the interactive database.

7. ELECTION OF CLASS III DIRECTOR: JEREMY M. LEVIN, DPHIL, MB BCHIR

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2026-06-10.

Combines 2 wordings of this item as funds reported it.

91% Majority: yes · of votes cast

FOR 91%9%

FOR: 87,219,707WITHHELD: 8,528,008

Ovid Therapeutics Inc.’s own tally for this item (“Elect Director: Jeremy M. Levin, DPhil, MB BChir”): 87,219,707 for, 8,528,008 withheld, per its Form 8-K filed 2026-06-11 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Share-of-outstanding not shown: votes cast exceed the reported share count, which usually means multiple share classes with different voting rights.

The 15 asset managers below cast 100% of the shares they voted on this item FOR (12,871,852 for, 0 against).

FOR 93%7%

FOR: 12,871,852 (92.8%)ABSTAIN: 996,598 (7.2%)

Largest asset managers voting on “ELECTION OF CLASS III DIRECTOR: JEREMY M. LEVIN, DPHIL, MB BCHIR” at Ovid Therapeutics Inc., 2025-2026
Asset manager	For	Abstain	Vote
Federated Hermes	5,354,264	0	For
Vanguard	5,215,305	9,248	For
MUTUAL FUND SERIES TRUST	1,934,257	0	For
Fidelity	0	964,624	Abstain
Invesco	101,611	0	For
Simplify Exchange Traded Funds	96,817	0	For
EA Series Trust	91,234	0	For
Charles Schwab	72,000	0	For
Victory Capital	0	13,166	Abstain
BlackRock	6,364	0	For
American Century	0	4,672	Abstain
Blackstone Alternative Investment Funds	0	2,900	Abstain
John Hancock	0	1,349	Abstain
Advisors' Inner Circle Fund III	0	635	Abstain
Dimensional	0	4	Abstain

8. RATIFICATION OF THE SELECTION OF KPMG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2026.

AUDIT-RELATEDMajority of the votes cast: yes

Meeting held 2026-06-10.

99.9% Majority: yes · of votes cast

FOR 99.9%

FOR: 130,845,667AGAINST: 32,505

Ovid Therapeutics Inc.’s own tally for this item (“Proposal 3: The Company's stockholders ratified the selection of KPMG LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2026 by the votes set forth in the tab”): 130,845,667 for, 32,505 against, per its Form 8-K filed 2026-06-11 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Share-of-outstanding not shown: votes cast exceed the reported share count, which usually means multiple share classes with different voting rights.

The 15 asset managers below cast 100% of the shares they voted on this item FOR (13,868,450 for, 0 against).

FOR 100%

FOR: 13,868,450 (100.0%)

Largest asset managers voting on “RATIFICATION OF THE SELECTION OF KPMG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL ” at Ovid Therapeutics Inc., 2025-2026
Asset manager	For	Vote
Federated Hermes	5,354,264	For
Vanguard	5,224,553	For
MUTUAL FUND SERIES TRUST	1,934,257	For
Fidelity	964,624	For
Invesco	101,611	For
Simplify Exchange Traded Funds	96,817	For
EA Series Trust	91,234	For
Charles Schwab	72,000	For
Victory Capital	13,166	For
BlackRock	6,364	For
American Century	4,672	For
Blackstone Alternative Investment Funds	2,900	For
John Hancock	1,349	For
Advisors' Inner Circle Fund III	635	For
Dimensional	4	For

9. TO APPROVE AN AMENDMENT TO OUR AMENDED AND RESTATED CERTIFICATE OF INCORPORATION, AS AMENDED TO DATE, TO INCREASE THE NUMBER OF AUTHORIZED SHARES OF COMMON STOCK FROM 125,000,000 TO 315,000,000.

CAPITAL STRUCTURE

Reported under meeting date 2025-12-11; no official results on file for that date.

100% fund support · no official result

FOR 100%

The 6 asset managers below cast 100% of the shares they voted on this item FOR (3,226,309 for, 0 against).

FOR: 3,226,309 (100.0%)

Largest asset managers voting on “TO APPROVE AN AMENDMENT TO OUR AMENDED AND RESTATED CERTIFICATE OF INCORPORATION, AS AMENDED TO DATE, TO INCRE” at Ovid Therapeutics Inc., 2025-2026
Asset manager	For	Vote
Vanguard	2,631,012	For
Fidelity	499,910	For
EA Series Trust	91,234	For
Blackstone Alternative Investment Funds	2,200	For
John Hancock	1,692	For
Advisors' Inner Circle Fund III	261	For

10. To approve, in accordance with Nasdaq Listing Rule 5635(c), the issuance and sale of securities to our Chief Executive Officer pursuant to the Securities Purchase Agreement, dated October 2, 2025, by and between the Company and the investors party thereto.

CAPITAL STRUCTURE

Reported under meeting date 2025-12-11; no official results on file for that date.

Combines 2 wordings of this item as funds reported it.

100% fund support · no official result

FOR 100%

The 6 asset managers below cast 100% of the shares they voted on this item FOR (3,226,309 for, 0 against).

FOR: 3,226,309 (100.0%)

Largest asset managers voting on “To approve, in accordance with Nasdaq Listing Rule 5635(c), the issuance and sale of securities to our Chief E” at Ovid Therapeutics Inc., 2025-2026
Asset manager	For	Vote
Vanguard	2,631,012	For
Fidelity	499,910	For
EA Series Trust	91,234	For
Blackstone Alternative Investment Funds	2,200	For
John Hancock	1,692	For
Advisors' Inner Circle Fund III	261	For

11. TO APPROVE, IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(D), THE ISSUANCE OF SHARES OF OUR COMMON STOCK UPON THE CONVERSION OF OUR SERIES B PREFERRED STOCK AND THE EXERCISE OF OUR SERIES A WARRANTS AND SERIES B WARRANTS.

CAPITAL STRUCTURE

Reported under meeting date 2025-12-11; no official results on file for that date.

100% fund support · no official result

FOR 100%

The 6 asset managers below cast 100% of the shares they voted on this item FOR (3,226,309 for, 0 against).

FOR: 3,226,309 (100.0%)

Largest asset managers voting on “TO APPROVE, IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(D), THE ISSUANCE OF SHARES OF OUR COMMON STOCK UPON TH” at Ovid Therapeutics Inc., 2025-2026
Asset manager	For	Vote
Vanguard	2,631,012	For
Fidelity	499,910	For
EA Series Trust	91,234	For
Blackstone Alternative Investment Funds	2,200	For
John Hancock	1,692	For
Advisors' Inner Circle Fund III	261	For

Largest Ovid Therapeutics Inc. shareholders voting in 2025-2026

Ranked by the number of Ovid Therapeutics Inc. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 71,109,514 shares outstanding at the time of that meeting.

Top Ovid Therapeutics Inc. shareholders by shares voted, 2025-2026
#	Asset manager	% of shares outstanding
1	Affinity Asset Advisors, LLC	11.88%
2	Rubric Capital Management LP	7.01%
3	BVF INC/IL	5.42%
4	BlackRock	5.18%
5	Vanguard	4.40%
6	Madison Avenue Partners, LP	3.46%
7	ACADIAN ASSET MANAGEMENT LLC	2.37%
8	KENNEDY CAPITAL MANAGEMENT LLC	2.12%
9	DRIEHAUS CAPITAL MANAGEMENT LLC	1.97%
10	GEODE CAPITAL MANAGEMENT, LLC	1.86%

Reported Ovid Therapeutics Inc. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

Ovid Therapeutics Inc. beneficial owners on record for the 2025-2026 proxy season
Holder	% outstanding	Disclosure
Entities affiliated with Janus Henderson	36.37%	DEF14A
SILV Fund Ltd.	25.32%	DEF14A
RA Capital Healthcare Fund, L.P.	24.54%	DEF14A
Affinity Healthcare Fund, LP	21.99%	DEF14A
Mutual Fund Series Trust, on behalf of Eventide Healthcare & Life Sciences Fund	19.62%	DEF14A
Eventide Asset Management, LLC	16.61%	13G
Entities affiliated with ADAR1 Capital Management, LLC	13.42%	DEF14A
BALYASNY ASSET MANAGEMENT L.P.	13.10%	13G
Takeda Pharmaceutical Company Limited	12.35%	DEF14A
Jeremy M. Levin	12.03%	13G

Percentages above are of 71,109,514 shares outstanding, as reported by Ovid Therapeutics Inc. on its Form 10-Q dated 2025-05-09 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Ovid Therapeutics Inc.’s 10-Q dated 2025-05-09. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At Ovid Therapeutics Inc.'s 2 shareholder meetings in the 2025-2026 proxy season (held 2025-07-09 and 2026-06-10), 117 asset managers reported how they voted in their SEC Form N-PX filings, covering 569 separate fund positions. Their filings are grouped here into 11 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item of the season, voted at the meeting held 2025-07-09 — ADVISORY APPROVAL OF THE COMPENSATION PAID TO OUR NAMED EXECUTIVE OFFICERS. — FOR was 98% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Ovid Therapeutics Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2025-07-10.

Ovid Therapeutics Inc. proxy season coverage: 2025-2026 (this page).